<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220225054120N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-05-11</date_registration>
      <primary_sponsor>Ilam University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of comparing bronchodilators with corticosteroids and bronchodilators in children with bronchiolitis</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of comparing bronchodilators with corticosteroids and bronchodilators in children with bronchiolitis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-05-07</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62207</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In the first stage, the researcher uses the main entry and exit conditions of the study to prepare a list of eligible patients to participate in this study. If you wish and consent to participate in this research study, general information and written consent. Will be taken from patients' families. Then 60 patients with bronchiolitis are randomly divided into control group or intervention group using block randomization method by hiding random allocation. The control group will receive only the standard treatment protocol, but the intervention group will receive corticosteroids in addition to the standard treatment protocol, Blinding description: The patient receives the drug (intervention or comparison group) in sealed packets encoded. The coding is done by one of the project partners and the doctor, the evaluator and the patient are blind.</study_design>
      <phase>3</phase>
      <hc_freetext>Bronchiolitis.</hc_freetext>
      <i_freetext>Intervention group: The first group: hydrocortisone with Oxycort brand 5 mg per weight (one dose) and bronchodilator as ventolin or salbutamol at a dose of 0.15 mg per weight with an interval of 20 minutes, up to one hour in three times. / The second group only bronchodilator In the form of ventolin or salbutamol at a dose of 0.15 mg per weight at intervals of 20 minutes, up to one hour in three doses.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Maleki</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>East Azarbaijan province, Kalibar city, Moallem street, Valfajr alley 2, No. 672</address>
        <city>Kaleibar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۵۴۶۱۸۳۸۱۸۸</zip>
        <telephone>+98 41 4444 2476</telephone>
        <email>z.maleki69@yahoo.com</email>
        <affiliation>Ilam University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>zahra maleki</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>East Azarbaijan province, Kalibar city, Moallem street, Valfajr alley 2, No. 672</address>
        <city>Kaleibar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۵۴۶۱۸۳۸۱۸۸</zip>
        <telephone>+98 41 4444 2476</telephone>
        <email>z.maleki69@yahoo.com</email>
        <affiliation>Ilam University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria Based on the standard definition of bronchiolitis, the first or second episode of respiratory distress with wheezing and clinical evidence of viral respiratory infection such as body temperature 38 ° C and above, tachypnea and tachycardia or Coryza symptoms.</inclusion_criteria>
      <agemin>2 months</agemin>
      <agemax>24 months</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of more than two episodes of respiratory distress in the past.
Chronic heart and lung disease
Immunodeficiency
Down Syndrome
Metabolic or neurological illness
History of prematurity (less than 34 weeks of Gesteitional age)
Use of mechanical ventilation in infancy
Positive family history of utopia
Ill child in need of hospitalization due to dehydration, decreased level of consciousness, lethargy or symptoms of respiratory failure</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J11.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Influenza due to unidentified influenza virus with other respiratory manifestations</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The first group: hydrocortisone with Oxycort brand 5 mg per weight (one dose) and bronchodilator as ventolin or salbutamol at a dose of 0.15 mg per weight with an interval of 20 minutes, up to one hour in three times. / The second group only bronchodilator In the form of ventolin or salbutamol at a dose of 0.15 mg per weight at intervals of 20 minutes, up to one hour in three doses</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>All infants 2 to 24 months of age with the first Wise attack who are diagnosed with bronchiolitis need to be hospitalized and receive oxygen. Timepoint: After initial evaluation (on arrival), second evaluation (1 hour appointment) (1 dose of hydrocortisone ampoule, 5 mg per kg body weight and ventolin nebulizer at a dose of 0.15 mg per kg body weight (minimum dose) 2.5 mg and a maximum of 5 mg) and continue ventilation every 20 minutes for up to 3 doses, including monitoring of oxygen prevalence (using pulse oximetry), respiration rate, and pulse rate. In addition to oxygen saturation, Pulse rate and respiration rate, RDA Score and Clinical Score will also be checked and recorded. Method of measurement: CBSS table.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ilam University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-01-08</approval_date>
        <contact_name>Ethics Committee of Ilam University of Medical Sciences</contact_name>
        <contact_address>Ilam, Bangangab, Research Blvd., Ilam University of Medical Sciences, ilam Ilam Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
